相似文献
1
Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.
J Natl Cancer Inst. 2016 Aug 30;109(1). doi: 10.1093/jnci/djw183. Print 2017 Jan.
2
[CRISPR/CAS9, the King of Genome Editing Tools].
Mol Biol (Mosk). 2017 Jul-Aug;51(4):582-594. doi: 10.7868/S0026898417040036.
3
Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9.
Methods. 2017 May 15;121-122:29-44. doi: 10.1016/j.ymeth.2017.05.009.
4
CRISPR-Cas9 system-driven site-specific selection pressure on Herpes simplex virus genomes.
Virus Res. 2018 Jan 15;244:286-295. doi: 10.1016/j.virusres.2017.03.010. Epub 2017 Mar 6.
5
Pea early-browning virus-mediated genome editing via the CRISPR/Cas9 system in Nicotiana benthamiana and Arabidopsis.
Virus Res. 2018 Jan 15;244:333-337. doi: 10.1016/j.virusres.2017.10.009. Epub 2017 Oct 16.
6
Improving CRISPR-Cas9 On-Target Specificity.
Curr Issues Mol Biol. 2018;26:65-80. doi: 10.21775/cimb.026.065. Epub 2017 Sep 7.
7
Guide RNA engineering for versatile Cas9 functionality.
Nucleic Acids Res. 2016 Nov 16;44(20):9555-9564. doi: 10.1093/nar/gkw908. Epub 2016 Oct 12.
8
CRISPR/Cas9 in Genome Editing and Beyond.
Annu Rev Biochem. 2016 Jun 2;85:227-64. doi: 10.1146/annurev-biochem-060815-014607. Epub 2016 Apr 25.
9
Kinetics of the CRISPR-Cas9 effector complex assembly and the role of 3'-terminal segment of guide RNA.
Nucleic Acids Res. 2016 Apr 7;44(6):2837-45. doi: 10.1093/nar/gkw138. Epub 2016 Mar 3.
10
Treating Genetic Disorders Using State-Of-The-Art Technology.
Curr Issues Mol Biol. 2018;26:33-46. doi: 10.21775/cimb.026.033. Epub 2017 Sep 7.
引用本文的文献
1
Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.
Cancer Res. 2022 Sep 2;82(17):3002-3015. doi: 10.1158/0008-5472.CAN-21-2519.
2
Nanotechnology for Age-Related Macular Degeneration.
Pharmaceutics. 2021 Nov 29;13(12):2035. doi: 10.3390/pharmaceutics13122035.
3
Selective targeting of the oncogenic G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression.
Theranostics. 2020 Apr 6;10(11):5137-5153. doi: 10.7150/thno.42325. eCollection 2020.
4
Rescue of TCA Cycle Dysfunction for Cancer Therapy.
J Clin Med. 2019 Dec 6;8(12):2161. doi: 10.3390/jcm8122161.
5
Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells. Therapeutic Implications.
Front Oncol. 2019 Aug 20;9:779. doi: 10.3389/fonc.2019.00779. eCollection 2019.
6
Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers.
PLoS Comput Biol. 2019 Mar 28;15(3):e1006658. doi: 10.1371/journal.pcbi.1006658. eCollection 2019 Mar.
7
miR-23a promotes invasion of glioblastoma HOXD10-regulated glial-mesenchymal transition.
Signal Transduct Target Ther. 2018 Dec 28;3:33. doi: 10.1038/s41392-018-0033-6. eCollection 2018.
8
CRISPR/Cas9 Application for Gene Copy Fate Survey of Polyploid Vertebrates.
Front Genet. 2018 Jul 20;9:260. doi: 10.3389/fgene.2018.00260. eCollection 2018.
9
STK3 is a therapeutic target for a subset of acute myeloid leukemias.
Oncotarget. 2018 May 22;9(39):25458-25473. doi: 10.18632/oncotarget.25238.
10
Glioblastoma: new therapeutic strategies to address cellular and genomic complexity.
Oncotarget. 2017 Dec 20;9(10):9540-9554. doi: 10.18632/oncotarget.23476. eCollection 2018 Feb 6.
本文引用的文献
1
Nucleosomes impede Cas9 access to DNA in vivo and in vitro.
Elife. 2016 Mar 17;5:e12677. doi: 10.7554/eLife.12677.
2
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.
Nat Biotechnol. 2016 Feb;34(2):184-191. doi: 10.1038/nbt.3437. Epub 2016 Jan 18.
3
CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.
Sci Rep. 2015 Sep 3;5:13734. doi: 10.1038/srep13734.
4
Oncolytic viruses: a new class of immunotherapy drugs.
Nat Rev Drug Discov. 2015 Sep;14(9):642-62. doi: 10.1038/nrd4663.
5
Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
Nature. 2015 Jul 23;523(7561):481-5. doi: 10.1038/nature14592. Epub 2015 Jun 22.
6
Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation.
Nat Biotechnol. 2014 Dec;32(12):1262-7. doi: 10.1038/nbt.3026. Epub 2014 Sep 3.
7
Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.
Nat Biotechnol. 2014 Sep;32(9):941-6. doi: 10.1038/nbt.2951. Epub 2014 Jun 22.
8
Clinical interpretation and implications of whole-genome sequencing.
JAMA. 2014 Mar 12;311(10):1035-45. doi: 10.1001/jama.2014.1717.
9
Genome engineering using the CRISPR-Cas9 system.
Nat Protoc. 2013 Nov;8(11):2281-2308. doi: 10.1038/nprot.2013.143. Epub 2013 Oct 24.
10
Mutational landscape and significance across 12 major cancer types.
Nature. 2013 Oct 17;502(7471):333-339. doi: 10.1038/nature12634.
Zotero 插件